I-Mab to Participate at the Truist Securities BioPharma Symposium
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on cancer immunotherapies, has announced its participation in the Truist Securities BioPharma Symposium on November 7, 2024. The company's management team, including Interim CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, and Senior Director of Investor Relations Tyler Ehler, will engage in one-on-one and small group meetings with investors during the event.
I-Mab (NASDAQ: IMAB), una azienda biotech globale con sede negli Stati Uniti e focalizzata sulle immunoterapie oncologiche, ha annunciato la sua partecipazione al Truist Securities BioPharma Symposium che si terrà il 7 novembre 2024. Il team di gestione dell'azienda, compresi l'Amministratore Delegato ad interim Sean Fu, il CFO Joe Skelton, il CMO Phillip Dennis e il Direttore Senior delle Relazioni con gli Investitori Tyler Ehler, parteciperà a incontri individuali e a piccoli gruppi con investitori durante l'evento.
I-Mab (NASDAQ: IMAB), una empresa biotecnológica global con sede en Estados Unidos enfocada en las inmunotherapias contra el cáncer, ha anunciado su participación en el Truist Securities BioPharma Symposium el 7 de noviembre de 2024. El equipo directivo de la empresa, incluyendo al CEO interino Sean Fu, al CFO Joe Skelton, al CMO Phillip Dennis y al Director Senior de Relaciones con Inversores Tyler Ehler, se reunirá en encuentros uno a uno y en grupos pequeños con inversores durante el evento.
I-Mab (NASDAQ: IMAB)는 미국에 본사를 둔 글로벌 바이오테크 회사로 암 면역 치료에 주력하고 있으며, 2024년 11월 7일 Truist Securities BioPharma Symposium에 참가한다고 발표했습니다. 회사 경영진은 임시 CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis, 투자자 관계 수석 이사 Tyler Ehler를 포함하여 행사 기간 동안 투자자와의 일대일 및 소규모 그룹 미팅에 참여할 예정입니다.
I-Mab (NASDAQ: IMAB), une entreprise biopharmaceutique mondiale basée aux États-Unis et spécialisée dans les immunothérapies contre le cancer, a annoncé sa participation au Truist Securities BioPharma Symposium le 7 novembre 2024. L'équipe de direction de l'entreprise, y compris le PDG par intérim Sean Fu, le CFO Joe Skelton, le CMO Phillip Dennis et le directeur senior des relations avec les investisseurs Tyler Ehler, participera à des réunions individuelles et à des groupes restreints avec des investisseurs lors de l'événement.
I-Mab (NASDAQ: IMAB), ein globales Biotech-Unternehmen mit Sitz in den USA, das sich auf Krebsimmuntherapien konzentriert, hat seine Teilnahme am Truist Securities BioPharma Symposium am 7. November 2024 angekündigt. DasManagement-Team des Unternehmens, darunter der Interims-CEO Sean Fu, CFO Joe Skelton, CMO Phillip Dennis und der Senior Director für Investor Relations Tyler Ehler, wird während der Veranstaltung persönliche und Kleingruppengespräche mit Investoren führen.
- None.
- None.
Event Details
Meeting Date | Thursday, November 7, 2024 |
Meetings | One-on-one and small group meetings: November 7, 2024 |
Management | Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO) Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) Tyler Ehler, Senior Director, Investor Relations |
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-participate-at-the-truist-securities-biopharma-symposium-302287758.html
SOURCE I-Mab Biopharma
FAQ
When is I-Mab (IMAB) participating in the Truist Securities BioPharma Symposium?
Which executives from I-Mab (IMAB) will attend the Truist Securities BioPharma Symposium?
What type of meetings will I-Mab (IMAB) conduct at the Truist Securities BioPharma Symposium?
What is I-Mab's (IMAB) primary business focus?
